EU safety review for Novartis's Gilenya
This article was originally published in Scrip
The European Medicines Agency has announced the start of a review of Novartis's multiple sclerosis treatment Gilenya (fingolimod) following cardiac safety concerns, and is advising increased monitoring of all new patients while it awaits the results.
You may also be interested in...
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.